CLAIMS

1. Anti-TNF and/or anti-IL-10 for use in a combination method of regressing, reducing or eliminating tumor cells in tumor tissue of a patient, the method comprising:

collecting monocyte cells from the patient;

culturing the monocyte cells to form immature dendritic cells;

introducing intratumorally a therapeutically effective amount of the immature dendritic cells to the patient;

collecting cytotoxic T lymphocyte and/or NKT cells from the patient;

culturing the cytotoxic T lymphocyte and/or NKT cells to form cultured cytotoxic T lymphocyte and/or NKT cells;

introducing intratumorally a therapeutically effective amount of the cultured cytotoxic T lymphocyte and/or NKT cells to the patient; and

introducing intratumorally a therapeutically effective amount of the anti-TNF and/or anti-IL-10 to the patient.

2. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the culturing is conducted in a medium comprising IL-2, CD3, and mixtures thereof.

3. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the re-introducing of the cultured cytotoxic T lymphocyte and/or NKT cells is in conjunction with an anti-inflammatory agent.

4. The anti-TNF and/or anti-IL-10 for use of claim 3, wherein the cultured cytotoxic T lymphocyte and/or NKT cells are combined with the anti-inflammatory agent to form a composition.

5. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the patient is a human.

6. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the introducing intratumorally of the anti-TNF and/or anti-IL-10 is carried out prior to the re-introducing intratumorally of the cultured cytotoxic T lymphocyte and/or NKT cells.

7. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the introducing intratumorally of the anti-TNF and/or anti-IL-10 is carried out following the re-introducing intratumorally of the cultured cytotoxic T lymphocyte and/or NKT cells.

8. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the introducing intratumorally of the anti-TNF and/or anti-IL-10 is carried out coincidently with the re-introducing intratumorally of the cultured cytotoxic T lymphocyte and/or NKT cells.

9. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the cytotoxic T lymphocyte is CD8+NK T cell population.

10. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein radiation therapy is excluded.

11. The anti-TNF and/or anti-IL-10 for use of claim 1, wherein the patient is subjected to therapy selected from the group consisting of chemotherapy, radiotherapy, antibody therapy, and combinations thereof.

12. Anti-TNF and/or anti-IL-10 for use in a combination method of regressing, reducing or eliminating tumor cells in tumor tissue of a patient, the method comprising:

a. introducing intratumorally a therapeutically effective amount of immature dendritic cells to the tumor tissue;

b. collecting cytotoxic T lymphocyte and/or NKT cells from the patient;

c. culturing the cytotoxic T lymphocyte and/or NKT cells collected from the patient to produce cultured cytotoxic T lymphocyte and/or NDT cells;

d. introducing intratumorally a therapeutically effective amount of the cultured cytotoxic T lymphocyte and/or NKT cells to the tumor tissue; and

e. introducing intratumorally a therapeutically effective amount of anti-TNF and/or anti-IL-10 to the tumor tissue,

wherein step b., step c. and step d. follow step a.

13. The anti-TNF and/or anti-IL-10 for use of claim 12, further comprising;

collecting monocyte cells from the patient; and

culturing the monocyte cells to form the immature dendritic cells prior to step a.

14. Anti-TNF and/or anti-IL-10 for use in a combination method of regressing, reducing or eliminating tumor cells in tumor tissue of a patient, the method comprising:

a. introducing intratumorally a therapeutically effective amount of immature dendritic cells to the tumor tissue;

b. inducing a therapeutically effective amount of cytotoxic T lymphocyte and/or NKT cells to the tumor tissue; and

c. introducing intratumorally a therapeutically effective amount of anti-TNF and/or anti-IL-10 to the tumor tissue,

wherein steps b and c follow step a.